CN115806962A - Phosphoenolpyruvate carboxylase mutant and application thereof - Google Patents
Phosphoenolpyruvate carboxylase mutant and application thereof Download PDFInfo
- Publication number
- CN115806962A CN115806962A CN202111082664.3A CN202111082664A CN115806962A CN 115806962 A CN115806962 A CN 115806962A CN 202111082664 A CN202111082664 A CN 202111082664A CN 115806962 A CN115806962 A CN 115806962A
- Authority
- CN
- China
- Prior art keywords
- mutant
- pepc
- leu
- host cell
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 title claims abstract description 75
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000004472 Lysine Substances 0.000 claims abstract description 38
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 239000002243 precursor Substances 0.000 claims abstract description 25
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 24
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 24
- 239000002157 polynucleotide Substances 0.000 claims abstract description 24
- 239000013604 expression vector Substances 0.000 claims abstract description 21
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 230000035772 mutation Effects 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 17
- 229940024606 amino acid Drugs 0.000 claims description 17
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 15
- 229940049906 glutamate Drugs 0.000 claims description 14
- 229930195712 glutamate Natural products 0.000 claims description 14
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 13
- 239000004473 Threonine Substances 0.000 claims description 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 11
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- 150000007524 organic acids Chemical class 0.000 claims description 9
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 claims description 8
- 229960002429 proline Drugs 0.000 claims description 8
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 7
- 241000186216 Corynebacterium Species 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 235000005985 organic acids Nutrition 0.000 claims description 7
- 241000186146 Brevibacterium Species 0.000 claims description 6
- 241000588698 Erwinia Species 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 6
- 241000588768 Providencia Species 0.000 claims description 6
- 241000589516 Pseudomonas Species 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 6
- 241000607720 Serratia Species 0.000 claims description 6
- 241000187747 Streptomyces Species 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 229940009098 aspartate Drugs 0.000 claims description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 229960002591 hydroxyproline Drugs 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 6
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 5
- 241001260189 Corynebacterium glutamicum Z188 Species 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- -1 glutamate amide Chemical class 0.000 claims description 5
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- 102220466685 Histone H4 transcription factor_I9L_mutation Human genes 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003121 arginine Drugs 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 102220166509 rs139299230 Human genes 0.000 claims description 4
- 102220283702 rs1555526673 Human genes 0.000 claims description 4
- 102200082874 rs33962676 Human genes 0.000 claims description 4
- 102220094481 rs63750016 Human genes 0.000 claims description 4
- 102200104255 rs746601313 Human genes 0.000 claims description 4
- 102220140462 rs747095857 Human genes 0.000 claims description 4
- 102220220559 rs748848510 Human genes 0.000 claims description 4
- 102200007259 rs763862849 Human genes 0.000 claims description 4
- 102200104040 rs78829338 Human genes 0.000 claims description 4
- 102220101444 rs878853485 Human genes 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- 241000807905 Corynebacterium glutamicum ATCC 14067 Species 0.000 claims description 3
- 241000305071 Enterobacterales Species 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- KJOMYNHMBRNCNY-UHFFFAOYSA-N pentane-1,1-diamine Chemical compound CCCCC(N)N KJOMYNHMBRNCNY-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 2
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 21
- 235000013922 glutamic acid Nutrition 0.000 abstract description 15
- 239000004220 glutamic acid Substances 0.000 abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 9
- 239000008103 glucose Substances 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 61
- 108090000623 proteins and genes Proteins 0.000 description 61
- 238000006467 substitution reaction Methods 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 22
- 239000012634 fragment Substances 0.000 description 21
- 229960002989 glutamic acid Drugs 0.000 description 16
- 239000013598 vector Substances 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 101710088194 Dehydrogenase Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000003209 gene knockout Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 4
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 102000034356 gene-regulatory proteins Human genes 0.000 description 4
- 108091006104 gene-regulatory proteins Proteins 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 3
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241000588914 Enterobacter Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 101150019455 gdh gene Proteins 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 101150044424 lysE gene Proteins 0.000 description 3
- 229940049920 malate Drugs 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 2
- QENJLXATANVWMR-UHFFFAOYSA-N 2-[(3-amino-3-imino-2-methylpropanethioyl)amino]acetic acid Chemical compound NC(=N)C(C)C(=S)NCC(O)=O QENJLXATANVWMR-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 108010092060 Acetate kinase Proteins 0.000 description 2
- LBYMZCVBOKYZNS-CIUDSAMLSA-N Ala-Leu-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O LBYMZCVBOKYZNS-CIUDSAMLSA-N 0.000 description 2
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 2
- 108010055400 Aspartate kinase Proteins 0.000 description 2
- 108020004652 Aspartate-Semialdehyde Dehydrogenase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010014468 Dihydrodipicolinate Reductase Proteins 0.000 description 2
- 101100137785 Escherichia coli (strain K12) proX gene Proteins 0.000 description 2
- 102100034013 Gamma-glutamyl phosphate reductase Human genes 0.000 description 2
- OXEMJGCAJFFREE-FXQIFTODSA-N Glu-Gln-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O OXEMJGCAJFFREE-FXQIFTODSA-N 0.000 description 2
- 102000005133 Glutamate 5-kinase Human genes 0.000 description 2
- 108700023479 Glutamate 5-kinases Proteins 0.000 description 2
- 108010016106 Glutamate-5-semialdehyde dehydrogenase Proteins 0.000 description 2
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 2
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 2
- 108010064711 Homoserine dehydrogenase Proteins 0.000 description 2
- 108020003285 Isocitrate lyase Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- PDQDCFBVYXEFSD-SRVKXCTJSA-N Leu-Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PDQDCFBVYXEFSD-SRVKXCTJSA-N 0.000 description 2
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 2
- 108010048581 Lysine decarboxylase Proteins 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 108700023175 Phosphate acetyltransferases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108090000612 Proline Oxidase Proteins 0.000 description 2
- 102000004177 Proline oxidase Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101150094017 aceA gene Proteins 0.000 description 2
- 101150006213 ackA gene Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 101150107204 asd gene Proteins 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 101150011371 dapA gene Proteins 0.000 description 2
- 101150073654 dapB gene Proteins 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 101150064198 gapN gene Proteins 0.000 description 2
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 108010071598 homoserine kinase Proteins 0.000 description 2
- 101150035025 lysC gene Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 101150023641 ppc gene Proteins 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 101150118057 proA gene Proteins 0.000 description 2
- 101150046501 proB gene Proteins 0.000 description 2
- 101150108812 proC gene Proteins 0.000 description 2
- 101150050071 proY gene Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 101150108780 pta gene Proteins 0.000 description 2
- 101150068263 putA gene Proteins 0.000 description 2
- 101150015622 pyk gene Proteins 0.000 description 2
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101150014006 thrA gene Proteins 0.000 description 2
- 101150072448 thrB gene Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VBNGJYNPUFWTKX-UHFFFAOYSA-N 10,10-diamino-1,6-dioxacyclotridecane-2,5,7,13-tetrone Chemical compound NC1(CCC(=O)OC(CCC(=O)OC(CC1)=O)=O)N VBNGJYNPUFWTKX-UHFFFAOYSA-N 0.000 description 1
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 1
- 108091000044 4-hydroxy-tetrahydrodipicolinate synthase Proteins 0.000 description 1
- 108020001657 6-phosphogluconate dehydrogenase Proteins 0.000 description 1
- 102000004567 6-phosphogluconate dehydrogenase Human genes 0.000 description 1
- 108010009924 Aconitate hydratase Proteins 0.000 description 1
- 102000009836 Aconitate hydratase Human genes 0.000 description 1
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 description 1
- MBWYUTNBYSSUIQ-HERUPUMHSA-N Ala-Asn-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N MBWYUTNBYSSUIQ-HERUPUMHSA-N 0.000 description 1
- XQJAFSDFQZPYCU-UWJYBYFXSA-N Ala-Asn-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N XQJAFSDFQZPYCU-UWJYBYFXSA-N 0.000 description 1
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 1
- YIGLXQRFQVWFEY-NRPADANISA-N Ala-Gln-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O YIGLXQRFQVWFEY-NRPADANISA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 1
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 1
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- RGQCNKIDEQJEBT-CQDKDKBSSA-N Ala-Leu-Tyr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RGQCNKIDEQJEBT-CQDKDKBSSA-N 0.000 description 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 1
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
- 101710199203 Ammonium transporter AmtB Proteins 0.000 description 1
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 1
- IIABBYGHLYWVOS-FXQIFTODSA-N Arg-Asn-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O IIABBYGHLYWVOS-FXQIFTODSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- MZRBYBIQTIKERR-GUBZILKMSA-N Arg-Glu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MZRBYBIQTIKERR-GUBZILKMSA-N 0.000 description 1
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 1
- SLNCSSWAIDUUGF-LSJOCFKGSA-N Arg-His-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O SLNCSSWAIDUUGF-LSJOCFKGSA-N 0.000 description 1
- OOIMKQRCPJBGPD-XUXIUFHCSA-N Arg-Ile-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O OOIMKQRCPJBGPD-XUXIUFHCSA-N 0.000 description 1
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 1
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 1
- NGYHSXDNNOFHNE-AVGNSLFASA-N Arg-Pro-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O NGYHSXDNNOFHNE-AVGNSLFASA-N 0.000 description 1
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
- ICRHGPYYXMWHIE-LPEHRKFASA-N Arg-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ICRHGPYYXMWHIE-LPEHRKFASA-N 0.000 description 1
- ASQKVGRCKOFKIU-KZVJFYERSA-N Arg-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ASQKVGRCKOFKIU-KZVJFYERSA-N 0.000 description 1
- XRNXPIGJPQHCPC-RCWTZXSCSA-N Arg-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)C(O)=O XRNXPIGJPQHCPC-RCWTZXSCSA-N 0.000 description 1
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 1
- GNKVBRYFXYWXAB-WDSKDSINSA-N Asn-Glu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O GNKVBRYFXYWXAB-WDSKDSINSA-N 0.000 description 1
- UBKOVSLDWIHYSY-ACZMJKKPSA-N Asn-Glu-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UBKOVSLDWIHYSY-ACZMJKKPSA-N 0.000 description 1
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 1
- PHJPKNUWWHRAOC-PEFMBERDSA-N Asn-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PHJPKNUWWHRAOC-PEFMBERDSA-N 0.000 description 1
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- ZAESWDKAMDVHLL-RCOVLWMOSA-N Asn-Val-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O ZAESWDKAMDVHLL-RCOVLWMOSA-N 0.000 description 1
- JNCRAQVYJZGIOW-QSFUFRPTSA-N Asn-Val-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNCRAQVYJZGIOW-QSFUFRPTSA-N 0.000 description 1
- KVMPVNGOKHTUHZ-GCJQMDKQSA-N Asp-Ala-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KVMPVNGOKHTUHZ-GCJQMDKQSA-N 0.000 description 1
- RGKKALNPOYURGE-ZKWXMUAHSA-N Asp-Ala-Val Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O RGKKALNPOYURGE-ZKWXMUAHSA-N 0.000 description 1
- UGIBTKGQVWFTGX-BIIVOSGPSA-N Asp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O UGIBTKGQVWFTGX-BIIVOSGPSA-N 0.000 description 1
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 1
- OGTCOKZFOJIZFG-CIUDSAMLSA-N Asp-His-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O OGTCOKZFOJIZFG-CIUDSAMLSA-N 0.000 description 1
- SCQIQCWLOMOEFP-DCAQKATOSA-N Asp-Leu-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SCQIQCWLOMOEFP-DCAQKATOSA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 101000780609 Bacillus subtilis (strain 168) Aspartokinase 1 Proteins 0.000 description 1
- 101000779368 Bacillus subtilis (strain 168) Aspartokinase 3 Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100034229 Citramalyl-CoA lyase, mitochondrial Human genes 0.000 description 1
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 1
- 102000006732 Citrate synthase Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100070376 Dictyostelium discoideum alad gene Proteins 0.000 description 1
- 101100310802 Dictyostelium discoideum splA gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108010046649 GDNP peptide Proteins 0.000 description 1
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- KDXKFBSNIJYNNR-YVNDNENWSA-N Gln-Glu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KDXKFBSNIJYNNR-YVNDNENWSA-N 0.000 description 1
- XJKAKYXMFHUIHT-AUTRQRHGSA-N Gln-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N XJKAKYXMFHUIHT-AUTRQRHGSA-N 0.000 description 1
- VGTDBGYFVWOQTI-RYUDHWBXSA-N Gln-Gly-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VGTDBGYFVWOQTI-RYUDHWBXSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- AMHIFFIUJOJEKJ-SZMVWBNQSA-N Gln-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N AMHIFFIUJOJEKJ-SZMVWBNQSA-N 0.000 description 1
- NHMRJKKAVMENKJ-WDCWCFNPSA-N Gln-Thr-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NHMRJKKAVMENKJ-WDCWCFNPSA-N 0.000 description 1
- ARYKRXHBIPLULY-XKBZYTNZSA-N Gln-Thr-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ARYKRXHBIPLULY-XKBZYTNZSA-N 0.000 description 1
- YMCPEHDGTRUOHO-SXNHZJKMSA-N Gln-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)N YMCPEHDGTRUOHO-SXNHZJKMSA-N 0.000 description 1
- BBFCMGBMYIAGRS-AUTRQRHGSA-N Gln-Val-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BBFCMGBMYIAGRS-AUTRQRHGSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 1
- PXHABOCPJVTGEK-BQBZGAKWSA-N Glu-Gln-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O PXHABOCPJVTGEK-BQBZGAKWSA-N 0.000 description 1
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- JGHNIWVNCAOVRO-DCAQKATOSA-N Glu-His-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGHNIWVNCAOVRO-DCAQKATOSA-N 0.000 description 1
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 1
- LZMQSTPFYJLVJB-GUBZILKMSA-N Glu-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N LZMQSTPFYJLVJB-GUBZILKMSA-N 0.000 description 1
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 1
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 1
- TWYSSILQABLLME-HJGDQZAQSA-N Glu-Thr-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYSSILQABLLME-HJGDQZAQSA-N 0.000 description 1
- PMSDOVISAARGAV-FHWLQOOXSA-N Glu-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 PMSDOVISAARGAV-FHWLQOOXSA-N 0.000 description 1
- HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 description 1
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 108020000311 Glutamate Synthase Proteins 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 1
- XRTDOIOIBMAXCT-NKWVEPMBSA-N Gly-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)CN)C(=O)O XRTDOIOIBMAXCT-NKWVEPMBSA-N 0.000 description 1
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 1
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- FCKPEGOCSVZPNC-WHOFXGATSA-N Gly-Ile-Phe Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FCKPEGOCSVZPNC-WHOFXGATSA-N 0.000 description 1
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 1
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- UMRIXLHPZZIOML-OALUTQOASA-N Gly-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CN UMRIXLHPZZIOML-OALUTQOASA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- COZMNNJEGNPDED-HOCLYGCPSA-N Gly-Val-Trp Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O COZMNNJEGNPDED-HOCLYGCPSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- BQYZXYCEKYJKAM-VGDYDELISA-N His-Cys-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQYZXYCEKYJKAM-VGDYDELISA-N 0.000 description 1
- LIEIYPBMQJLASB-SRVKXCTJSA-N His-Gln-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CN=CN1 LIEIYPBMQJLASB-SRVKXCTJSA-N 0.000 description 1
- SDTPKSOWFXBACN-GUBZILKMSA-N His-Glu-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O SDTPKSOWFXBACN-GUBZILKMSA-N 0.000 description 1
- MIHTTYXBXIRRGV-AVGNSLFASA-N His-Met-Arg Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N MIHTTYXBXIRRGV-AVGNSLFASA-N 0.000 description 1
- OWYIDJCNRWRSJY-QTKMDUPCSA-N His-Pro-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O OWYIDJCNRWRSJY-QTKMDUPCSA-N 0.000 description 1
- PZAJPILZRFPYJJ-SRVKXCTJSA-N His-Ser-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O PZAJPILZRFPYJJ-SRVKXCTJSA-N 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- JRHFQUPIZOYKQP-KBIXCLLPSA-N Ile-Ala-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O JRHFQUPIZOYKQP-KBIXCLLPSA-N 0.000 description 1
- RWIKBYVJQAJYDP-BJDJZHNGSA-N Ile-Ala-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RWIKBYVJQAJYDP-BJDJZHNGSA-N 0.000 description 1
- FVEWRQXNISSYFO-ZPFDUUQYSA-N Ile-Arg-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FVEWRQXNISSYFO-ZPFDUUQYSA-N 0.000 description 1
- JQLFYZMEXFNRFS-DJFWLOJKSA-N Ile-Asp-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N JQLFYZMEXFNRFS-DJFWLOJKSA-N 0.000 description 1
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 1
- AQTWDZDISVGCAC-CFMVVWHZSA-N Ile-Asp-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N AQTWDZDISVGCAC-CFMVVWHZSA-N 0.000 description 1
- KIMHKBDJQQYLHU-PEFMBERDSA-N Ile-Glu-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KIMHKBDJQQYLHU-PEFMBERDSA-N 0.000 description 1
- LPFBXFILACZHIB-LAEOZQHASA-N Ile-Gly-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)N LPFBXFILACZHIB-LAEOZQHASA-N 0.000 description 1
- BJECXJHLUJXPJQ-PYJNHQTQSA-N Ile-Pro-His Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N BJECXJHLUJXPJQ-PYJNHQTQSA-N 0.000 description 1
- IVXJIMGDOYRLQU-XUXIUFHCSA-N Ile-Pro-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O IVXJIMGDOYRLQU-XUXIUFHCSA-N 0.000 description 1
- ZNOBVZFCHNHKHA-KBIXCLLPSA-N Ile-Ser-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZNOBVZFCHNHKHA-KBIXCLLPSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- GRZSCTXVCDUIPO-SRVKXCTJSA-N Leu-Arg-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRZSCTXVCDUIPO-SRVKXCTJSA-N 0.000 description 1
- CUXRXAIAVYLVFD-ULQDDVLXSA-N Leu-Arg-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUXRXAIAVYLVFD-ULQDDVLXSA-N 0.000 description 1
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 1
- ZURHXHNAEJJRNU-CIUDSAMLSA-N Leu-Asp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZURHXHNAEJJRNU-CIUDSAMLSA-N 0.000 description 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 1
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
- OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- KTOIECMYZZGVSI-BZSNNMDCSA-N Leu-Phe-His Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 KTOIECMYZZGVSI-BZSNNMDCSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- URHJPNHRQMQGOZ-RHYQMDGZSA-N Leu-Thr-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O URHJPNHRQMQGOZ-RHYQMDGZSA-N 0.000 description 1
- ZGGVHTQAPHVMKM-IHPCNDPISA-N Leu-Trp-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)O)N ZGGVHTQAPHVMKM-IHPCNDPISA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- PNPYKQFJGRFYJE-GUBZILKMSA-N Lys-Ala-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNPYKQFJGRFYJE-GUBZILKMSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 1
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
- ATNKHRAIZCMCCN-BZSNNMDCSA-N Lys-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N ATNKHRAIZCMCCN-BZSNNMDCSA-N 0.000 description 1
- BXPHMHQHYHILBB-BZSNNMDCSA-N Lys-Lys-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BXPHMHQHYHILBB-BZSNNMDCSA-N 0.000 description 1
- 108020004687 Malate Synthase Proteins 0.000 description 1
- KUQWVNFMZLHAPA-CIUDSAMLSA-N Met-Ala-Gln Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O KUQWVNFMZLHAPA-CIUDSAMLSA-N 0.000 description 1
- DRXODWRPPUFIAY-DCAQKATOSA-N Met-Asn-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN DRXODWRPPUFIAY-DCAQKATOSA-N 0.000 description 1
- TZLYIHDABYBOCJ-FXQIFTODSA-N Met-Asp-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O TZLYIHDABYBOCJ-FXQIFTODSA-N 0.000 description 1
- AWGBEIYZPAXXSX-RWMBFGLXSA-N Met-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N AWGBEIYZPAXXSX-RWMBFGLXSA-N 0.000 description 1
- OXIWIYOJVNOKOV-SRVKXCTJSA-N Met-Met-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCNC(N)=N OXIWIYOJVNOKOV-SRVKXCTJSA-N 0.000 description 1
- GFDBWMDLBKCLQH-IHRRRGAJSA-N Met-Phe-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N GFDBWMDLBKCLQH-IHRRRGAJSA-N 0.000 description 1
- RMLLCGYYVZKKRT-CIUDSAMLSA-N Met-Ser-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O RMLLCGYYVZKKRT-CIUDSAMLSA-N 0.000 description 1
- QAVZUKIPOMBLMC-AVGNSLFASA-N Met-Val-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C QAVZUKIPOMBLMC-AVGNSLFASA-N 0.000 description 1
- VYDLZDRMOFYOGV-TUAOUCFPSA-N Met-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N VYDLZDRMOFYOGV-TUAOUCFPSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010021592 Pantothenate kinase Proteins 0.000 description 1
- 102100024122 Pantothenate kinase 1 Human genes 0.000 description 1
- MECSIDWUTYRHRJ-KKUMJFAQSA-N Phe-Asn-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O MECSIDWUTYRHRJ-KKUMJFAQSA-N 0.000 description 1
- LDSOBEJVGGVWGD-DLOVCJGASA-N Phe-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 LDSOBEJVGGVWGD-DLOVCJGASA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- BFYHIHGIHGROAT-HTUGSXCWSA-N Phe-Glu-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFYHIHGIHGROAT-HTUGSXCWSA-N 0.000 description 1
- GPSMLZQVIIYLDK-ULQDDVLXSA-N Phe-Lys-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O GPSMLZQVIIYLDK-ULQDDVLXSA-N 0.000 description 1
- BSTPNLNKHKBONJ-HTUGSXCWSA-N Phe-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O BSTPNLNKHKBONJ-HTUGSXCWSA-N 0.000 description 1
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 1
- FYQSMXKJYTZYRP-DCAQKATOSA-N Pro-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FYQSMXKJYTZYRP-DCAQKATOSA-N 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- FHZJRBVMLGOHBX-GUBZILKMSA-N Pro-Pro-Asp Chemical compound OC(=O)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1)C(O)=O FHZJRBVMLGOHBX-GUBZILKMSA-N 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 1
- NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 1
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- CNIIKZQXBBQHCX-FXQIFTODSA-N Ser-Asp-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O CNIIKZQXBBQHCX-FXQIFTODSA-N 0.000 description 1
- SMIDBHKWSYUBRZ-ACZMJKKPSA-N Ser-Glu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O SMIDBHKWSYUBRZ-ACZMJKKPSA-N 0.000 description 1
- YQQKYAZABFEYAF-FXQIFTODSA-N Ser-Glu-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQQKYAZABFEYAF-FXQIFTODSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 1
- UGGWCAFQPKANMW-FXQIFTODSA-N Ser-Met-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UGGWCAFQPKANMW-FXQIFTODSA-N 0.000 description 1
- UGTZYIPOBYXWRW-SRVKXCTJSA-N Ser-Phe-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O UGTZYIPOBYXWRW-SRVKXCTJSA-N 0.000 description 1
- XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 description 1
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102000011929 Succinate-CoA Ligases Human genes 0.000 description 1
- 108010075728 Succinate-CoA Ligases Proteins 0.000 description 1
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 1
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 1
- ZUUDNCOCILSYAM-KKHAAJSZSA-N Thr-Asp-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ZUUDNCOCILSYAM-KKHAAJSZSA-N 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- 102000006843 Threonine synthase Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- KIMOCKLJBXHFIN-YLVFBTJISA-N Trp-Ile-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O)=CNC2=C1 KIMOCKLJBXHFIN-YLVFBTJISA-N 0.000 description 1
- RRVUOLRWIZXBRQ-IHPCNDPISA-N Trp-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N RRVUOLRWIZXBRQ-IHPCNDPISA-N 0.000 description 1
- GFUOTIPYXKAPAH-BVSLBCMMSA-N Trp-Pro-Phe Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GFUOTIPYXKAPAH-BVSLBCMMSA-N 0.000 description 1
- KXFYAQUYJKOQMI-QEJZJMRPSA-N Trp-Ser-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 KXFYAQUYJKOQMI-QEJZJMRPSA-N 0.000 description 1
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 1
- AKFLVKKWVZMFOT-IHRRRGAJSA-N Tyr-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AKFLVKKWVZMFOT-IHRRRGAJSA-N 0.000 description 1
- NLMXVDDEQFKQQU-CFMVVWHZSA-N Tyr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLMXVDDEQFKQQU-CFMVVWHZSA-N 0.000 description 1
- NZFCWALTLNFHHC-JYJNAYRXSA-N Tyr-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NZFCWALTLNFHHC-JYJNAYRXSA-N 0.000 description 1
- CDHQEOXPWBDFPL-QWRGUYRKSA-N Tyr-Gly-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDHQEOXPWBDFPL-QWRGUYRKSA-N 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- NVZVJIUDICCMHZ-BZSNNMDCSA-N Tyr-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O NVZVJIUDICCMHZ-BZSNNMDCSA-N 0.000 description 1
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 1
- TYFLVOUZHQUBGM-IHRRRGAJSA-N Tyr-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TYFLVOUZHQUBGM-IHRRRGAJSA-N 0.000 description 1
- ABSXSJZNRAQDDI-KJEVXHAQSA-N Tyr-Val-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ABSXSJZNRAQDDI-KJEVXHAQSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 1
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 1
- QHFQQRKNGCXTHL-AUTRQRHGSA-N Val-Gln-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QHFQQRKNGCXTHL-AUTRQRHGSA-N 0.000 description 1
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 1
- PMXBARDFIAPBGK-DZKIICNBSA-N Val-Glu-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PMXBARDFIAPBGK-DZKIICNBSA-N 0.000 description 1
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 1
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 1
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- RQOMPQGUGBILAG-AVGNSLFASA-N Val-Met-Leu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O RQOMPQGUGBILAG-AVGNSLFASA-N 0.000 description 1
- YDVDTCJGBBJGRT-GUBZILKMSA-N Val-Met-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N YDVDTCJGBBJGRT-GUBZILKMSA-N 0.000 description 1
- WMRWZYSRQUORHJ-YDHLFZDLSA-N Val-Phe-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WMRWZYSRQUORHJ-YDHLFZDLSA-N 0.000 description 1
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 101150036393 aceB gene Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 101150113917 acnA gene Proteins 0.000 description 1
- 101150053555 acnB gene Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 101150014383 adhE gene Proteins 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 101150005925 aspC gene Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 101150008667 cadA gene Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 101150048956 coaA gene Proteins 0.000 description 1
- 101150109763 coaW gene Proteins 0.000 description 1
- 101150051152 coaX gene Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 101150064923 dapD gene Proteins 0.000 description 1
- 101150000582 dapE gene Proteins 0.000 description 1
- 101150057904 ddh gene Proteins 0.000 description 1
- 108010056578 diaminopimelate dehydrogenase Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 101150070837 eamA gene Proteins 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 101150077334 focA gene Proteins 0.000 description 1
- 108010008221 formate C-acetyltransferase Proteins 0.000 description 1
- 101150045461 gad gene Proteins 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 101150091570 gapA gene Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 101150106096 gltA gene Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010064177 glutamine synthetase I Proteins 0.000 description 1
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010011677 glyoxylate aminotransferase Proteins 0.000 description 1
- 101150014950 gnd gene Proteins 0.000 description 1
- 101150112623 hemA gene Proteins 0.000 description 1
- 101150055960 hemB gene Proteins 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 101150028254 icdA gene Proteins 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150108412 kgd gene Proteins 0.000 description 1
- 101150041134 ldcC gene Proteins 0.000 description 1
- 101150041530 ldha gene Proteins 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 101150003321 lpdA gene Proteins 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- VZXPDPZARILFQX-SCSAIBSYSA-N o-acetylserine Chemical compound CC(=O)OC[C@@H](N)C(O)=O VZXPDPZARILFQX-SCSAIBSYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 101150094986 pepC gene Proteins 0.000 description 1
- 101150111581 pflB gene Proteins 0.000 description 1
- 101150053253 pgi gene Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 101150000475 pntAB gene Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 101150060030 poxB gene Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101150100525 pykA gene Proteins 0.000 description 1
- 101150053304 pykF gene Proteins 0.000 description 1
- 101150117659 rhtA gene Proteins 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 101150000850 thrC gene Proteins 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 101150044161 tyrR gene Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a phosphoenolpyruvate carboxylase mutant, a polynucleotide encoding the mutant, an expression vector, a host cell and a method for producing a target compound using oxaloacetate as a precursor by using the mutant. The yield of lysine and glutamic acid and the glucose conversion rate of the strain expressing the PEPC mutant are obviously higher than those of the strain expressing wild PEPC, and the strain shows good application prospect.
Description
Technical Field
The invention belongs to the field of genetic engineering and molecular biology, and particularly relates to a phosphoenolpyruvate carboxylase mutant, an expression vector containing the mutant, a host cell, and a method for producing a target compound taking oxaloacetate as a precursor by using the mutant.
Background
The four-carbon anaplerosis pathway is a key pathway connecting glycolysis pathway and TCA cycle, while oxaloacetate is a key precursor of many amino acids and organic acids, and accumulation of target compounds that are precursors to oxaloacetate can be enhanced by enhancing the four-carbon anaplerosis pathway, such as lysine (Becker J, zelder O, hafner S, schroder H, wittmann C.Metab Eng,2011,13 (2): 159-168.), threonine (Lee KH, park JH, kimTY, kim HU, lee SY. Mol Syst Biol,2007,3 149.) and glutamic acid (Yoka, A., sawada, K.and da, M.Adv Eng Biotechnol,2017,159, 181-198.), and some organic acids such as succinic acid (Millar CS, chepo YP, liao JC, doy England Biotechnol,2017, 3262, J) (Biozoc J.8, J.).
Phosphoenolpyruvate Carboxylase (PEPC) is one of the key enzymes important in the four-carbon anaplerotic pathway,phosphoenolpyruvate and HCO can be converted 3- Conversion to oxaloacetate, but PEPC activity is tightly regulated in vivo, particularly by feedback inhibition of intracellular aspartate and malate (O' Regan M, thierbach G, bachmann B, vileval D, lepage P, viret jf. Gene,1989, 77. Researchers have previously obtained some PEPC mutants that have released feedback inhibition of aspartate and malate by evolutionary screening and rational design, and expression of these mutants helped to increase the accumulation of lysine, aspartate and glutamate (Yokota, a., sawada, k.and Wada, m.adv Biochem Eng Biotechnol,2017,159,181-198 chen, z., bommarmieddy, r.r., frank, d., rappert, s.and Zeng, a.p.appl Environ Microbiol,2014,80,1388-1393 Wada, m., sawada, k., ogura, k.shift, shift, y., hagiwarwara, t., sugimoto, m.and oni, uka.and yoka, 3763 zxft, 3763, bioeng,2016, 172, 2016. However, these mutants have a limited ability to increase the production of oxaloacetate-precursor chemicals, and some of them also have a severe effect on the growth of the cells. There is still a need in the art to develop more efficient mutants of PEPC in order to further increase the production of oxaloacetate-precursor chemicals without affecting the growth of the strain.
Disclosure of Invention
Aiming at the problems in the prior art, in order to obtain more PEPC mutants which are helpful for improving the accumulation of chemicals taking oxaloacetate as a precursor, the inventor utilizes a biosensor constructed in the early stage, constructs a random mutation library for PEPC, screens and obtains a plurality of dominant mutants, the PEPC mutants which are all helpful for improving the accumulation of lysine and glutamic acid and basically do not influence the growth, and the performances of partial mutants are superior to those of the mutants reported in the prior art. On the basis of this, the present invention has been completed.
The invention aims to provide a novel phosphoenolpyruvate carboxylase mutant, an expression vector containing the mutant, a host cell and a method for producing amino acid by using the mutant.
In a first aspect, the present invention provides a novel mutant phosphoenolpyruvate carboxylase, wherein the mutant is any one of the following group:
1, at least one of the following mutated amino acids is present in the polypeptide corresponding to the amino acid sequence shown in SEQ ID NO:
arg300His, asn806Ser, or
Lys152Glu, ser625Pro, ala674Thr, or
Ala200Val, val606Ala, ser625Pro, or
Phe356Ser, asn663Ser, or
Lys701Arg, lys702Glu, asn806Ser, or
Ala545Val, or
Ala589Val, or
Ile254Val, or
Gly17Asp, asn559Asp, or
Ile9Leu, or
His708Arg, ser757Leu, phe799Leu, or
Ala78Thr, tyr214His, his685Arg, or
Glu381Gln,Ile726Thr,Asp805Tyr。
2) 1, a polypeptide which has at least one mutation as described in 1) and has one or more bases added or deleted at both ends of the polypeptide shown in SEQ ID NO. 1. Preferably, 1, 2, 3, 4, 5 and 6 bases are added and deleted at two ends of the polypeptide shown in SEQ ID NO. 1.
3) 1, and at least one of the mutations described in 1). Preferably, the homology is at least 95% or more, at least 96% or more, at least 97% or more, at least 98% or more, at least 99% or more.
In a specific embodiment, the present disclosure provides a preferred phosphoenolpyruvate carboxylase mutant, wherein the mutant is a polypeptide having an amino acid sequence shown in SEQ ID NO. 1 and having any one of the following mutations:
arg300His, asn806Ser, or
Lys152Glu, ser625Pro, ala674Thr, or
Ala200Val, val606Ala, ser625Pro, or
Phe356Ser, asn663Ser, or
Lys701Arg, lys702Glu, asn806Ser, or
Ala545Val, or
Ala589Val, or
Ile254Val, or
Gly17Asp, asn559Asp, or
Ile9Leu, or
His708Arg, ser757Leu, phe799Leu, or
Ala78Thr, tyr214His, his685Arg, or
Glu381Gln,Ile726Thr,Asp805Tyr。
In a second aspect, the disclosure provides polynucleotides encoding the above mutants.
In a third aspect, the present disclosure provides an expression vector comprising the above mutant.
In a fourth aspect, the present disclosure provides a host cell comprising the above mutant.
In one embodiment, the host cell is a microorganism of the genera Escherichia (Escherichia), erwinia (Erwinia), serratia (Serratia), providencia (Providencia), enterobacter (Enterobacteria), salmonella (Salmonella), streptomyces (Streptomyces), pseudomonas (Pseudomonas), brevibacterium (Brevibacterium), corynebacterium (Corynebacterium).
In a further embodiment, the host cell is corynebacterium glutamicum, and optionally, the starting strain of the host cell is corynebacterium glutamicum ATCC13032, corynebacterium glutamicum ATCC13869, corynebacterium glutamicum ATCC 14067, corynebacterium glutamicum Z188, and derivatives thereof.
In a fifth aspect, the present disclosure provides a method of producing a compound of interest, wherein the method comprises producing the compound of interest in the presence of the mutant of the first aspect, the polynucleotide of the second aspect, the expression vector of the third aspect, or culturing the host cell of the fourth aspect to produce the compound of interest. Optionally, a step of separating the target compound from the culture medium is further included.
In a further embodiment, the target compound with oxaloacetate as precursor includes but is not limited to amino acid, organic acid or derivatives thereof, preferably including aspartate family amino acid (lysine, threonine, isoleucine, methionine), glutamate family amino acid (glutamate, proline, hydroxyproline, arginine, glutamate amide), and 5-aminolevulinic acid, etc., preferably organic acid includes succinic acid, α -ketoglutaric acid, malic acid, fumaric acid, etc., and preferred derivatives include but are not limited to pentanediamine, 5-amino pentanoic acid, glutaric acid, etc.
In summary, the present disclosure provides the use of a mutant of the first aspect, a polynucleotide of the second aspect, an expression vector of the third aspect, a host cell of the fourth aspect and a production method of the fifth aspect for the production of a compound of interest, precursor to oxaloacetate.
Advantageous effects of the disclosure
1. The PEPC mutant obtained by the method can obviously improve the yield (such as lysine and glutamic acid) of the target compound taking oxaloacetate as a precursor, and basically does not affect the growth of the strain, so that the production cost of the target compound taking oxaloacetate as a precursor can be further reduced, and the PEPC mutant has better industrial application potential.
2. The PEPC mutant obtained by the method provides a new idea for constructing a strain of a target compound taking oxaloacetate as a precursor.
Drawings
FIG. 1 flow cytometry analysis of PEPC random mutation library.
FIG. 2 analysis of fluorescence intensity of PEPC mutant library 96-well rescreened mutant.
Detailed Description
Definition of terms
The terms "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification can mean "one," but can also mean "one or more," at least one, "and" one or more than one.
As used in the claims and specification, the terms "comprising," "having," "including," or "containing" are intended to be inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
Throughout this specification, the term "about" means: a value includes the standard deviation of error for the device or method used to determine the value.
Although the present disclosure supports the definition of the term "or" as merely an alternative and "and/or," the term "or" in the claims means "and/or" unless it is explicitly stated that only alternatives or mutual exclusions between alternatives are mutually exclusive.
When used in the claims or specification, the term "range of values" is selected/preferred to include both the end points of the range and all natural numbers subsumed within the middle of the end points of the range with respect to the aforementioned end points of values.
The term "phosphoenolpyruvate carboxylase" of the present disclosure refers to a catalytic phosphoenolpyruvate and HCO 3- An enzyme that converts to oxaloacetate. As used herein, the phosphoenolpyruvate carboxylase is not particularly limited as long as it has a corresponding activity, and may be a phosphoenolpyruvate carboxylase derived from a microorganism of the genus Corynebacterium (e.g., corynebacterium glutamicum), but is not limited thereto. For example, the phosphoenolpyruvate carboxylase can be a polypeptide represented by the amino acid sequence of SEQ ID NO. 1 or a polypeptide having an amino acid sequence with at least 75%, specifically at least 80%, more specifically 85%, and even more specifically 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more homology to the amino acid sequence of SEQ ID NO. 1. In addition, amino acid sequences having deletions, modifications, substitutions or additions are also intended to be within the scope of the present disclosure if they have homology to the above sequences and have substantially the same or corresponding biological activity as the protein represented by SEQ ID NO. 1. In the present disclosure, any polynucleotide sequence encoding a phosphoenolpyruvate carboxylase can be within the scope of the present disclosure. For example, the polynucleotide sequence can be at least 75%, specifically at least 80%, more specifically 85%, and even more specifically 90%, 91%, 92% identical to the polynucleotide sequence of SEQ ID NO. 2%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more homologous polynucleotide sequence. In addition, a polynucleotide sequence encoding a protein may have various variants on a coding region within a range that does not change the amino acid sequence of the protein expressed from the coding region, based on codon degeneracy or considering codons preferred by an organism to express the protein.
Further, the phosphoenolpyruvate carboxylase mutants of the present disclosure may include not only the polypeptide having the amino acid sequence of SEQ ID NO. 1, but also phosphoenolpyruvate carboxylase mutants having homology of 75% or more, specifically 80% or more, more specifically 85% or more, and even more specifically 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% or more with the polypeptide having the amino acid sequence shown in SEQ ID NO. 1, as long as they have any one of the mutations of the present disclosure. It is obvious that amino acid sequences having substantially the same or corresponding biological activity as the polypeptide having the amino acid sequence of SEQ ID NO. 1 shall also fall within the scope of the present disclosure. The terms "phosphoenolpyruvate carboxylase", "PEPC", "PPC" according to the invention are identical and interchangeable.
The term "polynucleotide" of the present disclosure refers to a polymer composed of nucleotides. Polynucleotides may be in the form of individual fragments, or may be a component of a larger nucleotide sequence structure, derived from nucleotide sequences that have been isolated at least once in quantity or concentration, and which are capable of being recognized, manipulated, and recovered in sequence, and their component nucleotide sequences, by standard molecular biology methods (e.g., using cloning vectors). When a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C) in which "U" replaces "T". In other words, a "polynucleotide" refers to a polymer of nucleotides removed from other nucleotides (either individually or as a whole) or may be an integral part or component of a larger nucleotide structure, such as an expression vector or a polycistronic sequence. Polynucleotides include DNA, RNA, and cDNA sequences.
The term "homology" of the present disclosure refers to the percentage of identity between two polynucleotide or polypeptide portions. Homology between the sequences of one portion and another portion can be determined by techniques known in the art. For example, homology can be determined by directly aligning the sequence information of two polynucleotide molecules or two polypeptide molecules using readily available computer programs. Examples of computer programs may include BLAST (NCBI), CLC Main Workbench (CLC bio), megAlignTM (DNASTAR Inc.), and the like. In addition, the homology between polynucleotides can be determined by: polynucleotides are hybridized under conditions that form a stable double strand between homologous regions, cleaved with a single strand specific nuclease, and the cleaved fragments are then sized.
The term "wild-type" of the present disclosure refers to an object that can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism, can be isolated from a source in nature, and is not intentionally modified by man in the laboratory, is naturally occurring. As used in this disclosure, "naturally occurring" and "wild-type" are synonyms. In some embodiments, the wild-type PEPC in the present disclosure refers to a PEPC having an amino acid sequence as set forth in SEQ ID NO: 1.
The term "mutant" of the present disclosure refers to a polynucleotide that comprises alterations (i.e., substitutions, insertions, and/or deletions) at one or more (e.g., several) positions relative to a "wild-type", or "comparable" polynucleotide or polypeptide, wherein a substitution refers to the substitution of a nucleotide occupying a position with a different nucleotide.
In some embodiments, a "mutation" of the present disclosure is a "substitution", which is a mutation caused by the substitution of a base in one or more nucleotides with another, different base, also referred to as a base substitution mutation (mutation) or a point mutation (point mutation).
The term "conservative mutation" refers to a mutation that can normally maintain the function of a protein. A representative example of conservative mutations is conservative substitutions.
As used in this disclosure, the term "conservative substitution" refers to the replacement of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art and include those having basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid and glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan), β -branches (e.g., threonine, valine, and isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine). Examples of the substitution regarded as conservative substitution include substitution of Ala with Ser or Thr, substitution of Arg with Gln, his or Lys, substitution of Asn with Glu, gln, lys, his or Asp, substitution of Asp with Asn, glu or Gln, substitution of Cys with Ser or Ala, substitution of Gln with Asn, glu, lys, his, asp or Arg, substitution of Glu with Gly, asn, gln, lys or Asp, substitution of Gly with Pro, substitution of His with Asn, lys, gln, arg or Tyr, substitution of Ile with Leu, met, val or Phe, substitution of Leu with Ile, met, val or Phe, substitution of Lys with Asn, glu, gln, his or Arg, substitution of Met with Ile, leu, val or Phe, substitution of Phe with Trp, tyr, met, ile or Leu, substitution of Ser with Thr or Ala, substitution of Thr with Ser or Ala, substitution of Trp with Phe, tyr, his or Phe, and substitution of Met with Met or Phe. Furthermore, conservative mutations include naturally occurring mutations due to individual differences in the origin of the gene, differences in strain, species, and the like.
The term "corresponding to" as used herein has the meaning commonly understood by a person of ordinary skill in the art. Specifically, "corresponding to" means the position of one sequence corresponding to a specified position in the other sequence after alignment of the two sequences by homology or sequence identity. Thus, for example, with reference to "a polypeptide corresponding to SEQ ID NO:1 "if the amino acid residue at position 150 of the amino acid sequence shown in SEQ ID NO:1 with a6 × His tag at one end of the amino acid sequence shown in SEQ ID NO:1 may be at position 150 of 156.
The term "expression" of the present disclosure includes any step involving RNA production and protein production, including but not limited to: transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
The term "vector" of the present disclosure refers to a DNA construct containing a DNA sequence operably linked to suitable control sequences to express a gene of interest in a suitable host. "expression vector" refers to a DNA construct used to express, for example, a polynucleotide encoding a desired polypeptide. Recombinant expression vectors can include, for example, a collection comprising i) genetic elements that have a regulatory effect on gene expression, such as promoters and enhancers; ii) a structural or coding sequence that is transcribed into mRNA and translated into protein; and iii) transcriptional subunits of appropriate transcriptional and translational initiation and termination sequences. The recombinant expression vector is constructed in any suitable manner. The nature of the vector is not critical and any vector may be used, including plasmids, viruses, phages and transposons. Possible vectors for use in the present disclosure include, but are not limited to, chromosomal, non-chromosomal and synthetic DNA sequences, such as bacterial plasmids, phage DNA, yeast plasmids, and vectors derived from combinations of plasmids and phage DNA, DNA from viruses such as vaccinia, adenovirus, fowlpox, baculovirus, SV40 and pseudorabies.
The term "host cell" of the present disclosure refers to any cell type that comprises transformation, transfection, transduction, etc., of a PEPC mutant or expression vector of the present disclosure. The term "recombinant host cell" encompasses host cells which differ from the parent cell after introduction of a transcription initiation element or a recombinant expression vector, which is effected in particular by transformation.
The term "transformation" in the present disclosure has the meaning commonly understood by those skilled in the art, i.e., the process of introducing exogenous DNA into a host. The method of transformation includes any method of introducing a nucleic acid into a cell, including, but not limited to, electroporation, calcium phosphate precipitation, calcium chloride (CaCl) 2 ) Precipitation, microinjection, polyethylene glycol (PEG), DEAE-dextran, cationic liposome, and lithium acetate-DMSO.
The host cell of the present disclosure may be a prokaryotic cell or a eukaryotic cell, as long as it is a cell capable of containing the PEPC mutant of the present disclosure. In some embodiments, the host cell refers to a prokaryotic cell, in particular, the host cell is derived from a microorganism suitable for the fermentative production of a target compound (e.g., an L-amino acid) which is precursor to oxaloacetate, and may include strains of Escherichia (Escherichia), erwinia (Erwinia), serratia (Serratia), providencia (Providencia), enterobacter (enterobacter), salmonella (Salmonella), streptomyces (Streptomyces), pseudomonas (Pseudomonas), brevibacterium (Brevibacterium), corynebacterium (Corynebacterium), and the like, but is not limited thereto. Preferably, it may be Corynebacterium glutamicum. Preferably, corynebacterium glutamicum ATCC13032, corynebacterium glutamicum ATCC13869, corynebacterium glutamicum ATCC 14067, corynebacterium glutamicum Z188, and strains derived therefrom, and the like can be mentioned. Illustratively, the derivative strain may be any strain as long as the strain has the ability to produce a target compound (e.g., an L-amino acid) whose precursor is oxaloacetate.
Illustratively, the host cell is a lysine-producing host cell. In some embodiments, for lysine-producing host cells, can be in the Corynebacterium glutamicum ATCC13032 based on the expression of feedback inhibition of aspartate kinase derivative strain. In addition, lysine-producing host cells may also be other kinds of strains having lysine-producing ability.
In some embodiments, the lysine producing host cell may further include, but is not limited to, attenuated or reduced expression of one or more genes selected from the group consisting of:
a. the adhE gene encoding alcohol dehydrogenase;
b. the ackA gene encoding acetate kinase;
c. a pta gene encoding a phosphate acetyltransferase;
d. an ldhA gene encoding lactate dehydrogenase;
e. the focA gene encoding a formate transporter;
f. the pflB gene encoding pyruvate formate lyase;
g. a poxB gene encoding pyruvate oxidase;
h. the thrA gene of bifunctional enzyme for coding aspartokinase I/homoserine dehydrogenase I;
i. the thrB gene encoding homoserine kinase;
j. an ldcC gene encoding lysine decarboxylase; and
h. the cadA gene which codes for lysine decarboxylase.
In some embodiments, one or more genes selected from the group consisting of, but not limited to:
a. the dapA gene encoding dihydrodipicolinate synthase which relieves feedback inhibition by lysine;
b. a dapB gene encoding dihydrodipicolinate reductase;
c. a ddh gene encoding diaminopimelate dehydrogenase;
d. dapD encoding a tetrahydropyridyldicarboxylate succinylase and dapE encoding a succinyldiaminopimelate deacylase;
e. an asd gene encoding aspartate-semialdehyde dehydrogenase;
f. the ppc gene encoding phosphoenolpyruvate carboxylase;
g. the pntAB gene encoding nicotinamide adenine dinucleotide transhydrogenase;
i. the lysE gene of the transport protein which codes for lysine.
Illustratively, the host cell is a glutamate producing host cell. In some embodiments, the host cell for producing glutamic acid can be corynebacterium glutamicum Z188, or a derivative strain of corynebacterium glutamicum Z188. In some embodiments, one or more genes that may include, but are not limited to, those selected from the group consisting of:
a) Encoding the glutamate dehydrogenase gdh gene;
b) A gene encoding glutamine synthetase glnA;
c) Encoding the glutamate synthase gltBD gene;
d) Encoding an isocitrate dehydrogenase icdA gene;
e) Coding aconitate hydratase acnA/acnB gene;
f) Encoding the citrate synthase gltA gene;
g) The gene encoding pyruvate carboxylase pyc;
h) Encoding pyruvate dehydrogenase aceEF/lpdA gene;
i) The gene encoding pyruvate kinase pykA/pykF;
j) The gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase;
k) Encodes the glucose phosphate isomerase pgi gene.
In some embodiments, the host cell that produces glutamate may also include, but is not limited to, one or more genes attenuated or eliminated selected from the group consisting of:
a) Encoding the aceA gene of isocitrate lyase;
b) Encoding an alpha-ketoglutarate dehydrogenase kgd gene;
c) A gene encoding lactate dehydrogenase ldh;
d) Encoding the glutamate decarboxylase gad gene.
Illustratively, the host cell is a proline-producing host cell. In some embodiments, the proline-producing host cell may be escherichia coli or corynebacterium glutamicum, or a derivative strain thereof. In some embodiments, one or more genes that may include, but are not limited to, those selected from the group consisting of:
a) Encoding the glutamate kinase proB gene for the release of feedback inhibition;
b) The proA gene which codes for glutamate-5-semialdehyde dehydrogenase;
c) The proC gene which codes for the pyrrole-5-carboxylate dehydrogenase;
d) The gdh gene which codes for glutamate dehydrogenase;
e) The gene encoding pyruvate carboxylase pyc;
f) The gapN gene encoding glyceraldehyde-3-phosphate dehydrogenase;
g) Encoding l-proline efflux protein thrE or serE gene.
In some embodiments, the proline-producing host cell may also include, but is not limited to, attenuated or reduced expression of one or more genes selected from the group consisting of:
a) Encoding proline dehydrogenase/pyrrole-5-carboxylic acid dehydrogenase putA gene;
b) Encoding L-glutamic acid efflux protein mscCG gene;
c) Encoding the transporter proP/proY/proU gene.
Illustratively, the host cell is a host cell that produces hydroxyproline. In some embodiments, the host cell for producing hydroxyproline may be escherichia coli or corynebacterium glutamicum, or a derivative strain thereof. In some embodiments, one or more genes that may include, but are not limited to, those selected from the group consisting of:
a) A gene encoding proline hydroxylase;
b) Encoding the glutamate kinase proB gene for the release of feedback inhibition;
c) The proA gene which codes for glutamate-5-semialdehyde dehydrogenase;
d) The proC gene which codes for the pyrrole-5-carboxylate dehydrogenase;
e) Encoding the glutamate dehydrogenase gdh gene;
f) The gene encoding pyruvate carboxylase pyc;
g) The gapN gene encoding glyceraldehyde-3-phosphate dehydrogenase;
h) The gene encoding the ammonium transporter amtB;
i) Encoding the transporter proP/proY/proU gene.
In some embodiments, the hydroxyproline-producing host cell may also include, but is not limited to, attenuated or reduced expression of one or more genes selected from the group consisting of:
a) Encoding proline dehydrogenase/pyrrole-5-carboxylic acid dehydrogenase putA gene;
b) Encoding L-glutamic acid efflux protein mscCG gene;
c) Encoding L-proline efflux protein thrE or serE gene.
Illustratively, the host cell is a threonine producing host cell. In some embodiments, the threonine-producing host cell can be Escherichia coli or Corynebacterium glutamicum, or a derivative strain thereof. In some embodiments, one or more genes that may include, but are not limited to, those selected from the group consisting of:
a) Encoding aspartokinase III lysC gene;
b) Encoding aspartate semialdehyde dehydrogenase asd gene;
c) Encoding aspartokinase I thrA gene;
d) Encoding the homoserine kinase thrB gene;
e) Encoding threonine synthase thrC gene;
f) Encoding an aspartate aminotransferase aspC gene;
g) The coding 6-phosphogluconate dehydrogenase gnd gene.
In some embodiments, the threonine-producing host cell can be Escherichia coli or Corynebacterium glutamicum, or a derivative strain thereof. In some embodiments, one or more genes selected from, but not limited to, the following, may also be attenuated or eliminated in the threonine producing host cell:
a) A dapA gene encoding dihydrobipyridine synthase;
b) A dapB gene encoding dihydrodipicolinate reductase;
c) The ackA gene encoding acetate kinase;
d) A pta gene encoding a phosphate acetyltransferase;
e) Encoding the transcription regulatory factor tyrR gene.
Illustratively, the host cell is a host cell that produces 5-aminolevulinic acid. In some embodiments, the host cell for producing 5-aminolevulinic acid can be Escherichia coli or Corynebacterium glutamicum, and also can be a derivative strain thereof. In some embodiments, one or more genes in the 5-aminolevulinic acid-producing host cell, which may include but are not limited to those selected from the group consisting of:
a) A gene encoding 5-amino acid propionate synthetase hemA;
b) The gene encoding pyruvate carboxylase pyc;
c) The gene encoding pantothenate kinase coaA;
d) The rhtA gene encoding threonine/homoserine transporter;
e) Encoding cysteine/O-acetylserine transporter eamA gene;
f) The gene agt which codes for alanine, glyoxylate aminotransferase.
g) A gene encoding an antioxidant-related protein.
In some embodiments, the host cell for producing 5-amino acid propionic acid may be Escherichia coli or Corynebacterium glutamicum, or a derivative strain thereof. In some embodiments, the host cell that produces 5-amino acid propionic acid may also include, but is not limited to, one or more genes selected from the group consisting of:
a) Encoding succinyl-coa synthetase sucCD gene;
b) A gene encoding succinate dehydrogenase sdhAB;
c) The gene encoding 5-aminolevulinic acid dehydratase hemB;
d) Encoding the aceA gene of isocitrate lyase;
e) Encoding malate synthase aceB gene.
The term "oxaloacetate-precursor target compound" of the present disclosure includes, but is not limited to, amino acids including aspartate family amino acids (lysine, threonine, isoleucine, methionine), glutamate family amino acids (glutamate, proline, hydroxyproline, arginine, glutamate amide), and 5-aminolevulinic acid, etc., organic acids including succinic acid, α -ketoglutarate, malate, fumarate, etc., and derivatives thereof including, but not limited to, pentanediamine, glutarate, etc. By the method, the yield of the target compound taking oxaloacetate as a precursor of the strain can be improved.
The term "culturing" of the present disclosure may be carried out according to a conventional method in the art, including, but not limited to, a well plate culture, a shake flask culture, a batch culture, a continuous culture, a fed-batch culture, and the like, and various culture conditions such as temperature, time, pH of a medium, and the like may be appropriately adjusted according to actual circumstances.
Unless defined otherwise in the disclosure or clearly indicated by the background, all technical and scientific terms used in the disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
Examples
Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.
The experimental techniques and experimental procedures used in this example are, unless otherwise specified, conventional techniques, e.g., those in the following examples, in which specific conditions are not specified, and generally according to conventional conditions such as Sambrook et al, molecular cloning: conditions described in a Laboratory Manual (New York: cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommendations. The materials, reagents and the like used in the examples are commercially available from normal sources unless otherwise specified.
Example 1 construction and engineering of lysine biosensors
Carrying out whole gene synthesis according to the reported sequence information of the eyfp gene (GeneBank No. CCD28585.1), and carrying out PCR amplification by using a primer eyfp-F/eyfp-R to obtain an eyfp gene fragment; PCR amplification was carried out using Corynebacterium glutamicum ATCC13032 genome (Gene ID: 2830649) as a template and lysGE-F/lysGE-R as a primer to obtain a fragment of lysGE Gene; the full-length plasmid was PCR-reverse-amplified using the plasmid pTRCmob (Qian Liu, et al, J Biotechnol,2007,132, 273-279) as a template and pTRCmob-Rev-F/pTRCmob-Rev-R as primers to obtain a linearized vector fragment. After the three fragments are purified and recovered, a plasmid vector, a lysGE gene fragment and an eyfp gene fragment are connected by using recombinase, and a correct recombinant vector is named as pLysGE through transformation, enzyme digestion and sequencing verification. And designing a point mutation primer LysGE-mut-F/R, and performing reverse amplification by PCR, fragment purification and transformation by taking pLysGE as a template to obtain the lysine biosensor pLysGE58 with widened response concentration range and remarkably enhanced response strength to lysine. The response principle of the lysine biosensor is that when the concentration of intracellular lysine is low, the regulatory protein LysG cannot be combined with the lysine, so that the transcription of a fluorescent protein gene cannot be started by regulating a lysE gene promoter; when the intracellular lysine reaches a certain concentration, the regulatory protein LysG is combined with the lysine, so that the conformation of the LysG is changed, and then the regulatory protein is combined with a promoter of lysE to start the expression of the downstream reporter gene yellow fluorescent protein.
Example 2 pepc knock-out Strain construction
According to a lysine strain construction method (Becker, J., et al. Metab. Eng.,2011,13,159-168) disclosed in the literature, threonine at the 311 th position of aspartokinase (lysC gene code) on a Corynebacterium glutamicum ATCC13032 genome is mutated into isoleucine by a pK18 mobsacB-based homologous recombination technology, and a strain SCgL30 with certain lysine synthesis capacity is constructed. To exclude the genomic expression of wild-type PEPC from interfering with plasmid-overexpressed PEPC mutants, we knocked out the PEPC gene of the SCgL30 genome using CRISPR-Cas 9-based gene knock-out methods reported in the literature (Liu, j., et al. Micro.cell fact.,2017,16,205). The specific experimental process is as follows:
(1) Construction of pepc Gene knockout plasmid pgRNA-delta pepc
Designing primers pepc-up-F/R and pepc-down-F/R respectively according to the disclosed genome sequence of Corynebacterium glutamicum ATCC13032, and obtaining upstream and downstream homologous arm fragments for pepc gene knockout by PCR amplification by taking the ATCC13032 genome as a template; meanwhile, pgRNA2 (Liu, J., et al. Microb. Cell fact.,2017,16,205.) is used as a template, a framework fragment 1 is amplified by using a primer pepc-pgRNA-2/pepc-pgRNA-3, and a framework fragment 2 with pepc-sgRNA (N20, 5'-CGTGCGGGATCAGCGGACGA-3') is amplified by using gRNA-pepc/pgRNA-1 as a primer. And purifying and recovering the four fragments, and recombining and connecting to obtain the pepc gene knockout plasmid pgRNA-delta pepc.
(2) Pepc Gene knockout on SCgL30 Strain chromosome
The knockout plasmid pCas9 (Liu, J., et al. Microb. Cell fact, 2017,16,205) and pgRNA- Δ pepc were co-transformed into competent cells of the strain SCgL30 by an electric pulse method, 1mL of TSB medium preheated at 46 ℃ was added, incubated at 46 ℃ for 6min, incubated at 30 ℃ for 3h, and coated with a coating containing 50 μ M IPTG; the recombinant transformants were obtained by culturing in TSB solid medium containing 25. Mu.g/mL kanamycin and 5. Mu.g/mL chloramphenicol at 30 ℃ for 2 days. Wherein the TSB culture medium comprises the following components: glucose, 5g/L; 5g/L of yeast powder; soybean peptone, 9g/L; 3g/L of urea; succinic acid, 0.5g/L; k 2 HPO 4 ·3H 2 O,1g/L;MgSO 4 ·7H 2 O,0.1g/L; biotin, 0.01mg/L; vitamin B1,0.1mg/L; MOPS,20g/L. Verifying a transformant by using a verification primer pepc-TF/TR to confirm that a target gene on a chromosome of the strain is successfully knocked out, and then discarding the pCas9 plasmid at a high temperature of 37 ℃ to obtain a pepc gene knocked-out strain named ZPCgL1. The recombinant vector pLysGE58 carrying the lysine biosensor in example 1 was transformed into ZPGGL 1 to obtain the selection host strain ZPGGL 1/pLysGE58.
Example 3 construction of PEPC and its mutant expression vectors
A primer pepc-tac-F/R is designed according to the published genome sequence of the Corynebacterium glutamicum ATCC13032, and a pepc gene fragment is obtained by PCR amplification by taking the ATCC13032 genome as a template. Designing a primer pXMJ19-Rev-2F/2R according to the sequence information of the plasmid pXMJ19, obtaining a linearized vector fragment by PCR reverse amplification by taking the plasmid pXMJ19 as a template, recovering the two fragments, and recombining and connecting to obtain the pepc over-expression vector pXMJ19-pepc.
The information on the PEPC mutant that released feedback inhibition by aspartic acid and malic acid was reported in the literature (Yokota, A., sawada, K.and W.ada, M.Adv Biochem Eng Biotechnol,2017,159,181-198; chen, Z, bommareddy, R.R., frank, D, rappert, S.and Zeng, A.P.appl Environ Microbiol,2014,80,1388-1393), designing mutation primers D299N-F/R and N917G-F/R of D299N and N917G mutant respectively, PCR amplifying plasmid fragment by taking pXMJ19-PEPC as a template, recovering and transforming E.coli DH5 alpha competent cells to obtain PEPC respectively D299N Or PEPC N917G The expression vector pXMJ19-pepc D299N And pXMJ19-pepc N917G As a positive control plasmid. Empty plasmid pXMJ19, negative control plasmid pXMJ19-pepc and positive control plasmid pXMJ19-pepc D299N And pXMJ19-pepc N917G ZPGGL 1/pLysGE58 is respectively transformed to obtain control strains for PEPC mutant screening and rescreening evaluation.
Example 4 construction of PEPC random mutation library
The recombinant vector pXMJ19-pepc containing pepc gene is used as a template, and 0.05-0.5mM MnCl is added by using a primer pepc-mut-2F/2R 2 Obtaining pepc gene segments with different mutation rates by error-prone PCR amplification under the condition of (1). Meanwhile, pXMJ19-pepc is used as a template, and a primer pPEPC-Rev-F/R is used for obtaining a linearized vector framework through PCR reverse amplification. The two fragments are recovered, recombined and connected, chemically transformed into E.coli DH5 alpha competent cells, and cultured overnight at 37 ℃. And scraping colonies from the plate, extracting mixed plasmids, and obtaining PEPC random mutation libraries with different mutation rates.
Example 5 PEPC random mutation library flow cytometry sorting
The PEPC random mutation libraries with different mutation rates obtained in example 4 were mixed in equimolar proportions, electrically pulsed into the strain ZPCGL1/pLysGE58, resuscitated at 30 ℃ for 2h, and the resuscitated solution was inoculated into TSB broth containing 25. Mu.g/mL kanamycin and 5. Mu.g/mL chloramphenicol and cultured at 30 ℃ for 16h to obtain a library of strains for screening. The negative control strains ZPGL 1/pLysGE58/pXMJ19 and ZPGCL 1/pLysGE58/pXMJ19-pepc and the mutant library strains were inoculated into a TSB broth containing 25. Mu.g/mL kanamycin and 5. Mu.g/mL chloramphenicol, cultured at 30 ℃ for 8 hours, transferred to 24-well plates containing 1mL CGXII medium (containing 25. Mu.g/mL kanamycin, 5. Mu.g/mL chloramphenicol and 25. Mu.M ITPG), and the wells were plated at 30 ℃ in 24-well platesPerforming shake culture for 6h, wherein the CGXII medium comprises the following components: 50g/L glucose,16.5g/L NH 4 Cl,5g/L urea,1g/L KH 2 PO 4 ,1g/L K 2 HPO 4 ,42g/L MOPS,0.25g/L MgSO 4 ,0.01g/LFeSO 4 ·2H 2 O,0.01g/L MnSO 4 ·H 2 O,0.001g/L ZnSO 4 ·7H 2 O,0.2mg/L CuSO 4 ,0.02mg/L NiCL·6H 2 O,0.01g/L CaCl 2 0.03g/L protocatechuic acid,0.2mg/L biotin, and 0.1mg/L vitamin B1. The cell concentration of the culture was diluted to 0.1OD with PBS buffer 600nm The fluorescence intensity of the above-mentioned strain was analyzed by a flow cytometer, and the analysis results are shown in FIG. 1. The flow cytometer sorting region (R15) of the mutant library strain was selected based on the fluorescence distribution of the strain ZPGCL 1/pLysGE58/pXMJ19, the strain ZPGCL 1/pLysGE58/pXMJ19-PEPC expressing the wild-type PEPC containing 0.02% of fluorescence enhanced cells in the R15 region, and the mutant library strain containing 0.38% of fluorescence enhanced cells in the R15 region. According to the response principle of the lysine biosensor, when the concentration of lysine is higher, the regulatory protein LysG is combined with the lysine, and further combined with the promoter of the lysE gene, so that the expression of downstream fluorescent reporter gene protein is started. Thus, the above data indicate that the mutant library contains more PEPC mutant strains that produce increased amounts of lysine, and subsequently, cells in this region are sorted and monocloned.
Example 6 re-screening of PEPC mutant libraries and Effect on lysine Synthesis
Single-cell colonies previously obtained by flow cytometry sorting were randomly picked and a portion of the single colonies was inoculated into a 96-well plate containing 200. Mu.L of TSB broth (containing 25. Mu.g/mL kanamycin and 5. Mu.g/mL chloramphenicol), together with the empty plasmid control strain ZPCGL1/pLysGE58/pXMJ19, the wild-type PEPC overexpression strain ZPCGL1/pLysGE58/pXMJ19-PEPC and the positive control strain CgPL 1/pLysGE58/pXMJ19-PEPC D299N And ZPGGL 1/pLysGE58/pXMJ19-pepc N917G Culturing at 30 deg.C and 800rpm for 8h in a well plate shaker. The seed solution was transferred at 5% (V/V) to a medium containing 200. Mu.LCGXII (containing 25. Mu.M ITPG, 25. Mu.g/mL kanamycin and 5. Mu.g/well in the blood vessel of the plant)mL chloramphenicol, 100g/L primary glucose) in a 96-well plate, incubated at 30 ℃ for 6 hours at 800rpm in a plate shaker, diluted 20-fold with PBS buffer, and then the fluorescence intensity and OD of eYFP were measured with a microplate reader (spectra max M5, molecular Devices, λ excitation =488nm, λ emission =520 nm) 600nm As shown in FIG. 2, the mutants having fluorescence values stronger than those of the wild-type PEPC-overexpressing strain ZPCGL1/pLysGE58/pXMJ19-PEPC were sequenced and the mutation sites thereof were analyzed. Meanwhile, continuously culturing the mutant strains with enhanced fluorescence values, stopping culturing after 36h, and detecting OD by using a microplate reader 600nm SBA-40D biosensing analyzer (institute of biological sciences, shandong province, academy of sciences) measures lysine concentration and residual glucose concentration. The mutant information and the lysine yield are shown in table 1, and it can be seen that the lysine yield and the glucose conversion rate of the screened PEPC-expressing mutant are obviously higher than those of wild PEPC-expressing strains, the effect is better than that of reported D299N and N917G mutants, and the application prospect is good.
TABLE 1 PEPC mutants and their lysine production
Example 7 PEPC mutant expression vector construction
To verify the effect of the PEPC mutants obtained in the above examples in the production of other oxaloacetate-precursor target compounds, we randomly selected the 2-50 and 5-66 mutants obtained in the above examples and tested the effect of the two mutants in the production of glutamate.
Firstly, designing a primer pepc-250-F/R according to the sequence of a pepc gene, and respectively taking strains containing 2-50 mutants and 5-66 mutants as templates to obtain corresponding gene fragments through PCR amplification. Designing a primer PEPC-pXMJ19-F/R according to the sequence information of the plasmid pXMJ19, obtaining a linearized vector fragment by PCR reverse amplification by taking the plasmid pXMJ19 as a template, recovering the two fragments, recombining and connecting to obtain the PEPC mutant expression vector pXMJ19-PEPC 2-50 And pXMJ19-pepc 5-66 。
Example 8 construction of PEPC wild type and mutant overexpression strains
Competent cells of a glutamic acid-producing strain Z188 (NCBI Reference Sequence: NZ _ AKXP 00000000.1) were prepared by a method reported in the literature (Ruan Y, et al, biotechnol. Lett.,2015, 2445-52.), 1. Mu.g of a PEPC mutant expression vector and control vectors pXMJ19 and pXMJ19-PEPC were electroporated into Z188 competent cells obtained as described above, respectively, a TSB solid medium containing 5. Mu.g/mL of chloramphenicol was spread on the cells, and the cells were cultured at 30 ℃ for 1 day to obtain recombinant strains Z188/pXMJ19, Z188/pXMJ19-PEPC, and Z188/pXMJ19-PEPC 2-50 、Z188/pXMJ19-pepc 5-66 。
Example 9 Effect of PEPC mutant expression on glutamate Synthesis
To test the effect of the overexpression of PEPC mutant by Corynebacterium glutamicum on the production of glutamic acid by the strain, fermentation tests were carried out on the recombinant strains obtained in example 8, respectively. The seed culture medium comprises the following components: glucose, 50g/L; 0.7g/L phosphoric acid; ammonium sulfate, 10g/L; mgSO (MgSO) 4 ·7H 2 O,0.8g/L; 3g/L of corn starch; 10g/L of urea; peptone, 1g/L; 0.5g/L of yeast powder; initial pH7.0. Compared with a seed culture medium, the fermentation culture medium is not added with peptone and yeast powder, and 84g/L MOPS is additionally added. The strains were first inoculated into seed medium for 14h and the cultures were inoculated as seeds into 24-well plates containing 800. Mu.L of fermentation medium per well, starting OD 600 Controlling the culture at 30 ℃ for 29h under the condition of 0.3, controlling the rotation speed of a pore plate shaker to be 800rpm, enabling 3 strains to be parallel, detecting the yield of the glutamic acid and the consumption of the glucose after the fermentation is finished, and calculating the conversion rate of the saccharic acid from the glucose to the glutamic acid. The results are shown in table-2, the glutamic acid yield of the PEPC mutant expression strain is obviously higher than that of the empty plasmid and the control strain expressing wild PEPC, and the saccharic acid conversion rate is greatly improved. Therefore, the PEPC mutant obtained by the invention has better application prospect in the production of glutamic acid and derivatives thereof.
TABLE-2 overexpression of PEPC mutant strains and their glutamic acid fermentation yields
TABLE 3 primers used in the examples of the present disclosure
In addition, this example only shows an example of the PEPC mutant improving the yield of lysine and glutamic acid, and as mentioned above, since oxaloacetate is a key precursor of many amino acids and organic acids, the accumulation of target compounds using oxaloacetate as a precursor, such as lysine, threonine, glutamic acid, and some organic acids, can be improved by strengthening the four-carbon anaplerosis pathway, so those skilled in the art can understand that the PEPC mutant of the present disclosure can also increase the yield of target compounds using oxaloacetate as a precursor, and the method for producing target compounds using oxaloacetate as a precursor by using the PEPC mutant of the present disclosure is within the protection scope of the present disclosure.
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
SEQUENCE LISTING
<110> institute of biotechnology for Tianjin industry of Chinese academy of sciences
<120> phosphoenolpyruvate carboxylase mutant and application thereof
<130> CPCN21411230
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 919
<212> PRT
<213> Corynebacterium glutamicum
<400> 1
Met Thr Asp Phe Leu Arg Asp Asp Ile Arg Phe Leu Gly Gln Ile Leu
1 5 10 15
Gly Glu Val Ile Ala Glu Gln Glu Gly Gln Glu Val Tyr Glu Leu Val
20 25 30
Glu Gln Ala Arg Leu Thr Ser Phe Asp Ile Ala Lys Gly Asn Ala Glu
35 40 45
Met Asp Ser Leu Val Gln Val Phe Asp Gly Ile Thr Pro Ala Lys Ala
50 55 60
Thr Pro Ile Ala Arg Ala Phe Ser His Phe Ala Leu Leu Ala Asn Leu
65 70 75 80
Ala Glu Asp Leu Tyr Asp Glu Glu Leu Arg Glu Gln Ala Leu Asp Ala
85 90 95
Gly Asp Thr Pro Pro Asp Ser Thr Leu Asp Ala Thr Trp Leu Lys Leu
100 105 110
Asn Glu Gly Asn Val Gly Ala Glu Ala Val Ala Asp Val Leu Arg Asn
115 120 125
Ala Glu Val Ala Pro Val Leu Thr Ala His Pro Thr Glu Thr Arg Arg
130 135 140
Arg Thr Val Phe Asp Ala Gln Lys Trp Ile Thr Thr His Met Arg Glu
145 150 155 160
Arg His Ala Leu Gln Ser Ala Glu Pro Thr Ala Arg Thr Gln Ser Lys
165 170 175
Leu Asp Glu Ile Glu Lys Asn Ile Arg Arg Arg Ile Thr Ile Leu Trp
180 185 190
Gln Thr Ala Leu Ile Arg Val Ala Arg Pro Arg Ile Glu Asp Glu Ile
195 200 205
Glu Val Gly Leu Arg Tyr Tyr Lys Leu Ser Leu Leu Glu Glu Ile Pro
210 215 220
Arg Ile Asn Arg Asp Val Ala Val Glu Leu Arg Glu Arg Phe Gly Glu
225 230 235 240
Gly Val Pro Leu Lys Pro Val Val Lys Pro Gly Ser Trp Ile Gly Gly
245 250 255
Asp His Asp Gly Asn Pro Tyr Val Thr Ala Glu Thr Val Glu Tyr Ser
260 265 270
Thr His Arg Ala Ala Glu Thr Val Leu Lys Tyr Tyr Ala Arg Gln Leu
275 280 285
His Ser Leu Glu His Glu Leu Ser Leu Ser Asp Arg Met Asn Lys Val
290 295 300
Thr Pro Gln Leu Leu Ala Leu Ala Asp Ala Gly His Asn Asp Val Pro
305 310 315 320
Ser Arg Val Asp Glu Pro Tyr Arg Arg Ala Val His Gly Val Arg Gly
325 330 335
Arg Ile Leu Ala Thr Thr Ala Glu Leu Ile Gly Glu Asp Ala Val Glu
340 345 350
Gly Val Trp Phe Lys Val Phe Thr Pro Tyr Ala Ser Pro Glu Glu Phe
355 360 365
Leu Asn Asp Ala Leu Thr Ile Asp His Ser Leu Arg Glu Ser Lys Asp
370 375 380
Val Leu Ile Ala Asp Asp Arg Leu Ser Val Leu Ile Ser Ala Ile Glu
385 390 395 400
Ser Phe Gly Phe Asn Leu Tyr Ala Leu Asp Leu Arg Gln Asn Ser Glu
405 410 415
Ser Tyr Glu Asp Val Leu Thr Glu Leu Phe Glu Arg Ala Gln Val Thr
420 425 430
Ala Asn Tyr Arg Glu Leu Ser Glu Ala Glu Lys Leu Glu Val Leu Leu
435 440 445
Lys Glu Leu Arg Ser Pro Arg Pro Leu Ile Pro His Gly Ser Asp Glu
450 455 460
Tyr Ser Glu Val Thr Asp Arg Glu Leu Gly Ile Phe Arg Thr Ala Ser
465 470 475 480
Glu Ala Val Lys Lys Phe Gly Pro Arg Met Val Pro His Cys Ile Ile
485 490 495
Ser Met Ala Ser Ser Val Thr Asp Val Leu Glu Pro Met Val Leu Leu
500 505 510
Lys Glu Phe Gly Leu Ile Ala Ala Asn Gly Asp Asn Pro Arg Gly Thr
515 520 525
Val Asp Val Ile Pro Leu Phe Glu Thr Ile Glu Asp Leu Gln Ala Gly
530 535 540
Ala Gly Ile Leu Asp Glu Leu Trp Lys Ile Asp Leu Tyr Arg Asn Tyr
545 550 555 560
Leu Leu Gln Arg Asp Asn Val Gln Glu Val Met Leu Gly Tyr Ser Asp
565 570 575
Ser Asn Lys Asp Gly Gly Tyr Phe Ser Ala Asn Trp Ala Leu Tyr Asp
580 585 590
Ala Glu Leu Gln Leu Val Glu Leu Cys Arg Ser Ala Gly Val Lys Leu
595 600 605
Arg Leu Phe His Gly Arg Gly Gly Thr Val Gly Arg Gly Gly Gly Pro
610 615 620
Ser Tyr Asp Ala Ile Leu Ala Gln Pro Arg Gly Ala Val Gln Gly Ser
625 630 635 640
Val Arg Ile Thr Glu Gln Gly Glu Ile Ile Ser Ala Lys Tyr Gly Asn
645 650 655
Pro Glu Thr Ala Arg Arg Asn Leu Glu Ala Leu Val Ser Ala Thr Leu
660 665 670
Glu Ala Ser Leu Leu Asp Val Ser Glu Leu Thr Asp His Gln Arg Ala
675 680 685
Tyr Asp Ile Met Ser Glu Ile Ser Glu Leu Ser Leu Lys Lys Tyr Ala
690 695 700
Ser Leu Val His Glu Asp Gln Gly Phe Ile Asp Tyr Phe Thr Gln Ser
705 710 715 720
Thr Pro Leu Gln Glu Ile Gly Ser Leu Asn Ile Gly Ser Arg Pro Ser
725 730 735
Ser Arg Lys Gln Thr Ser Ser Val Glu Asp Leu Arg Ala Ile Pro Trp
740 745 750
Val Leu Ser Trp Ser Gln Ser Arg Val Met Leu Pro Gly Trp Phe Gly
755 760 765
Val Gly Thr Ala Leu Glu Gln Trp Ile Gly Glu Gly Glu Gln Ala Thr
770 775 780
Gln Arg Ile Ala Glu Leu Gln Thr Leu Asn Glu Ser Trp Pro Phe Phe
785 790 795 800
Thr Ser Val Leu Asp Asn Met Ala Gln Val Met Ser Lys Ala Glu Leu
805 810 815
Arg Leu Ala Lys Leu Tyr Ala Asp Leu Ile Pro Asp Thr Glu Val Ala
820 825 830
Glu Arg Val Tyr Ser Val Ile Arg Glu Glu Tyr Phe Leu Thr Lys Lys
835 840 845
Met Phe Cys Val Ile Thr Gly Ser Asp Asp Leu Leu Asp Asp Asn Pro
850 855 860
Leu Leu Ala Arg Ser Val Gln Arg Arg Tyr Pro Tyr Leu Leu Pro Leu
865 870 875 880
Asn Val Ile Gln Val Glu Met Met Arg Arg Tyr Arg Lys Gly Asp Gln
885 890 895
Ser Glu Gln Val Ser Arg Asn Ile Gln Leu Thr Met Asn Gly Leu Ser
900 905 910
Thr Ala Leu Arg Asn Ser Gly
915
Claims (11)
1. A phosphoenolpyruvate carboxylase mutant, wherein the mutant is any one of the group consisting of:
1) 1, at least one of the following mutated amino acids is present in the polypeptide corresponding to the amino acid sequence shown in SEQ ID NO:
arg300His, asn806Ser, or
Lys152Glu, ser625Pro, ala674Thr, or
Ala200Val, val606Ala, ser625Pro, or
Phe356Ser, asn663Ser, or
Lys701Arg, lys702Glu, asn806Ser, or
Ala545Val, or
Ala589Val, or
Ile254Val, or
Gly17Asp, asn559Asp, or
Ile9Leu, or
His708Arg, ser757Leu, phe799Leu, or
Ala78Thr, tyr214His, his685Arg, or
Glu381Gln,Ile726Thr,Asp805Tyr。
2) 1, a polypeptide which has at least one mutation as described in 1) and has one or more bases added or deleted at both ends of the polypeptide shown in SEQ ID NO. 1. Preferably, 1, 2, 3, 4, 5 and 6 bases are added and deleted at two ends of the polypeptide shown in SEQ ID NO. 1.
3) A polypeptide having at least 90% homology with the polypeptide shown in SEQ ID NO. 1 and having at least any one of the mutations described in 1). Preferably, the homology is at least 95% or more, at least 96% or more, at least 97% or more, at least 98% or more, at least 99% or more.
2. The mutant phosphoenolpyruvate carboxylase according to claim 1, wherein the mutant is a polypeptide having an amino acid sequence as set forth in SEQ ID No. 1 and having any one of the following mutations:
arg300His, asn806Ser, or
Lys152Glu, ser625Pro, ala674Thr, or
Ala200Val, val606Ala, ser625Pro, or
Phe356Ser, asn663Ser, or
Lys701Arg, lys702Glu, asn806Ser, or
Ala545Val, or
Ala589Val, or
Ile254Val, or
Gly17Asp, asn559Asp, or
Ile9Leu, or
His708Arg, ser757Leu, phe799Leu, or
Ala78Thr, tyr214His, his685Arg, or
Glu381Gln,Ile726Thr,Asp805Tyr。
3. A polynucleotide encoding the phosphoenolpyruvate carboxylase mutant according to claim 1 to 2.
4. An expression vector comprising the phosphoenolpyruvate carboxylase mutant according to claim 1 to 2.
5. A host cell comprising the mutant phosphoenolpyruvate carboxylase of claims 1 to 2.
6. The host cell according to claim 5, characterized in that the host cell is a microorganism of the genera Escherichia (Escherichia), erwinia (Erwinia), serratia (Serratia), providencia (Providencia), enterobacteria (Enterobacteria), salmonella (Salmonella), streptomyces (Streptomyces), pseudomonas (Pseudomonas), brevibacterium (Brevibacterium), corynebacterium (Corynebacterium).
7. The host cell of claim 6, wherein the host cell is Corynebacterium glutamicum, and optionally wherein the starting strain of the host cell is Corynebacterium glutamicum ATCC13032, corynebacterium glutamicum ATCC13869, corynebacterium glutamicum ATCC 14067, corynebacterium glutamicum Z188, and derivatives thereof.
8. A method for producing a target compound which is a precursor to oxaloacetate, comprising producing the target compound in the presence of the mutant of any one of claims 1-2, the polynucleotide of claim 3, the expression vector of claim 4, or culturing the host cell of claims 5-7 to produce the target compound.
9. The method of claim 8, further comprising the step of separating the target compound from the culture medium.
10. Method for the production of oxaloacetate-precursor target compounds according to claims 8-9, characterized in that said oxaloacetate-precursor target compounds include but are not limited to amino acids, organic acids or their derivatives, preferably including aspartate family amino acids (lysine, threonine, isoleucine, methionine), glutamate family amino acids (glutamate, proline, hydroxyproline, arginine, glutamate amide), and 5-aminolevulinic acid, etc., preferably organic acids including succinic acid, α -ketoglutaric acid, malic acid, fumaric acid, preferably derivatives including but not limited to pentanediamine, 5-amino pentanoic acid, glutaric acid, etc.
11. Use of a phosphoenolpyruvate carboxylase mutant according to claims 1 to 2, a polynucleotide according to claim 3, an expression vector according to claim 4 and/or a host cell according to claims 5 to 7 for the production of a target compound species which is precursor for oxaloacetate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111082664.3A CN115806962A (en) | 2021-09-15 | 2021-09-15 | Phosphoenolpyruvate carboxylase mutant and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111082664.3A CN115806962A (en) | 2021-09-15 | 2021-09-15 | Phosphoenolpyruvate carboxylase mutant and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115806962A true CN115806962A (en) | 2023-03-17 |
Family
ID=85482059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111082664.3A Pending CN115806962A (en) | 2021-09-15 | 2021-09-15 | Phosphoenolpyruvate carboxylase mutant and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115806962A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07111890A (en) * | 1993-08-24 | 1995-05-02 | Ajinomoto Co Inc | Variant phosphoenolpyruvate carboxylase, its gene and production of amino acid |
CN1133615A (en) * | 1993-08-24 | 1996-10-16 | 味之素株式会社 | Variant phosphoenolypyruvate carboxylase, gene thereof, and process for producing amino acid |
CN101100661A (en) * | 2007-06-25 | 2008-01-09 | 清华大学 | Phosphoric acid enol type pyruvate carboxylase and coding gene thereof |
CN110195087A (en) * | 2019-05-16 | 2019-09-03 | 黑龙江伊品生物科技有限公司 | With the method for the bacterial fermentation production L-lysine for changing ppc gene |
-
2021
- 2021-09-15 CN CN202111082664.3A patent/CN115806962A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07111890A (en) * | 1993-08-24 | 1995-05-02 | Ajinomoto Co Inc | Variant phosphoenolpyruvate carboxylase, its gene and production of amino acid |
CN1133615A (en) * | 1993-08-24 | 1996-10-16 | 味之素株式会社 | Variant phosphoenolypyruvate carboxylase, gene thereof, and process for producing amino acid |
CN101100661A (en) * | 2007-06-25 | 2008-01-09 | 清华大学 | Phosphoric acid enol type pyruvate carboxylase and coding gene thereof |
CN110195087A (en) * | 2019-05-16 | 2019-09-03 | 黑龙江伊品生物科技有限公司 | With the method for the bacterial fermentation production L-lysine for changing ppc gene |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11667936B2 (en) | Modified polypeptide with attenuated activity of citrate synthase and method for producing L-amino acid using the same | |
JP4846021B2 (en) | L-threonine-producing mutant microorganism and method for producing L-threonine using the same | |
US10526586B2 (en) | Pyruvate dehydrogenase variants, a microorganism comprising the same and a method for producing L-amino acid using the same | |
KR101991206B1 (en) | cAMP receptor protein variant and method for producing L-amino acid using the same | |
WO2022017221A1 (en) | Mutant of glutamate dehydrogenase gene promoter and application thereof | |
WO2022037338A1 (en) | Polynucleotide having promoter activity and application of polynucleotide in producing amino acid | |
KR101991207B1 (en) | cAMP receptor protein variant and method for producing L-amino acid using the same | |
CN113249347B (en) | Mutants of pyruvate dehydrogenase and methods for producing L-amino acids using the same | |
US10253339B2 (en) | Gluconate repressor variant, microorganism containing the same producing L-lysine, and method for producing L-lysine | |
WO2022017223A1 (en) | Mutant of pyruvate carboxylase gene promoter and use thereof | |
CN113278620B (en) | Mutant hypertonic inducible promoter Pprox and application thereof | |
CN115806962A (en) | Phosphoenolpyruvate carboxylase mutant and application thereof | |
CA3163266A1 (en) | Novel modified polypeptide with attenuated activity of citrate synthase and method for producing l-amino acid using the same | |
RU2812048C1 (en) | Pyruvate carboxylase gene promoter mutant and its application | |
RU2812048C9 (en) | Pyruvate carboxylase gene promoter mutant and its application | |
CN115449519B (en) | Polynucleotide having promoter activity based on dapB gene and use thereof | |
US20240084314A1 (en) | Mdh gene-based polynucleotide having promoter activity and use thereof | |
WO2008018722A1 (en) | A microorganism whose activity of aspartate semialdehyde dehydrogenase is enhanced and the process for producing l-threonine using the microorganism | |
CN117737021A (en) | Mutant citrate synthase and use thereof | |
CN115322989A (en) | Polynucleotide having promoter activity, use thereof, and method for producing target compound | |
CN115322990A (en) | Polynucleotides having promoter activity and use thereof for producing target compounds | |
CN115746110A (en) | Mutant of transcriptional regulatory factor LysG and application thereof | |
CN115490761A (en) | Recombinant microorganism constructed based on lysine efflux protein and method for producing lysine | |
CN115746111A (en) | Mutant of transcription regulatory factor LysG and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |